How advances in personalized medicine will change rheumatology

Personalized Medicine

Volumn 15, Issue 2, 2018, Pages 75-78

  Selmi, Carlo ^a,b   Kon, Elizaveta ^a,c   Santis, Maria De ^a   Favalli, Ennio G ^d   Cimaz, Rolando ^e,f   Generali, Elena ^a   Sinigaglia, Luigi ^d  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c HUMANITAS UNIVERSITY   (Italy)

^d ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

Author keywords

connective tissue disease; osteoarthritis; pediatric rheumatology; psoriatic arthritis; rheumatoid arthritis; spondyloarthritis

Indexed keywords

ABATACEPT; BELIMUMAB; C REACTIVE PROTEIN; CALGRANULIN; COLLAGEN TYPE 2; CXCL13 CHEMOKINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HLA B27 ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 6; METHOTREXATE; MICRORNA; RITUXIMAB; TOCILIZUMAB;

CLINICAL FEATURE; CLINICAL PRACTICE; CONNECTIVE TISSUE DISEASE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOBLOTTING; JUVENILE RHEUMATOID ARTHRITIS; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PATIENT MONITORING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; ARTHRITIS; GENETICS; PROCEDURES; TRENDS;

ARTHRITIS; HUMANS; PRECISION MEDICINE; RHEUMATOLOGY;

EID: 85041950348     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme-2017-0079     Document Type: Note

References (22)

1. Favalli EG, Pregnolato F, Biggioggero M et al. Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry. Arthritis Care Res. (Hoboken) 68(4), 432-439 (2016).
2. Castro-Villegas C, Perez-Sanchez C, Escudero A et al. Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFalpha. Arthritis Res. Ther. 17, 49 (2015).
3. Sokolove J, Schiff M, Fleischmann R et al. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: Two-year results from the AMPLE trial. Ann. Rheum. Dis. 75(4), 709-714 (2016).
4. Sellam J, Hendel-Chavez H, Rouanet S et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label study. Arthritis Rheum. 63(4), 933-938 (2011).
5. Juarez M, Bang H, Hammar F et al. Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann. Rheum. Dis. 75(6), 1099-1107 (2016).
6. Dennis G, Jr, Holweg CT, Kummerfeld SK et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res. Ther. 16(2), R90 (2014).
7. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N. Engl. J. Med. 376(10), 957-970 (2017).
8. Generali E, Scire CA, Favalli EG, Selmi C. Biomarkers in psoriatic arthritis: A systematic literature review. Expert Rev. Clin. Immunol. 12(6), 651-660 (2016).
9. Coates LC, Kavanaugh A, Mease PJ et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 68(5), 1060-1071 (2016).
10. Gossec L, Smolen JS, Ramiro S et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann. Rheum. Dis. 75(3), 499-510 (2016).
11. Karsdal MA, Michaelis M, Ladel C et al. Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future. Osteoarthritis Cartilage 24(12), 2013-2021 (2016).
12. Sirotti S, Generali E, Ceribelli A, Isailovic N, De Santis M, Selmi C. Personalized medicine in rheumatology: The paradigm of serum autoantibodies. Auto Immun Highlights 8(1), 10 (2017).
13. Weckerle CE, Franek BS, Kelly JA et al. Network analysis of associations between serum interferon-alpha activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 63(4), 1044-1053 (2011).
14. Merrill JT, Immermann F, Whitley M et al. The biomarkers of lupus disease study: A bold approach may mitigate interference of background immunosuppressants in clinical trials. Arthritis Rheumatol. 69(6), 1257-1266 (2017).
15. Furst DE, Clements PJ, Harris R, Ross M, Levy J, Paulus HE. Measurement of clinical change in progressive systemic sclerosis: A 1 year double-blind placebo-controlled trial of N-acetylcysteine. Ann. Rheum. Dis. 38(4), 356-361 (1979).
16. Haddon DJ, Wand HE, Jarrell JA et al. Proteomic analysis of sera from individuals with diffuse cutaneous systemic sclerosis reveals a multianalyte signature associated with clinical improvement during imatinib mesylate treatment. J. Rheumatol. 44(5), 631-638 (2017).
17. Lilleker JB, Vencovsky J, Wang G et al. The EuroMyositis registry: An international collaborative tool to facilitate myositis research. Ann. Rheum. Dis. 77(1), 30-39 (2017).
18. European Commission: CORDIS. http://cordis. europa. eu/project/rcn/207205 en. html
19. Zajc Avramovic M, Dolzan V, Toplak N, Accetto M, Lusa L, Avcin T. Relationship between polymorphisms in methotrexate pathway genes and outcome of methotrexate treatment in a cohort of 119 patients with juvenile idiopathic arthritis. J. Rheumatol. 44(8), 1216-1223 (2017).
20. Cimaz R, Cazalis MA, Reynaud C et al. IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors. Ann. Rheum. Dis. 66(7), 900-904 (2007).
21. Foell D, Wulffraat N, Wedderburn LR et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: A randomized clinical trial. JAMA 303(13), 1266-1273 (2010).
22. Banchereau R, Hong S, Cantarel B et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165(3), 551-565 (2016).